Mohammed Azim
Family Medicine · Manassas, VANPI 1467550236
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 1,356 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AstraZeneca at 26.9% of the total. Reporting peaked in 2021 at $5,233 and has fallen 55.2% since, to $2,342 in 2025. Among family medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,356 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- AbbVie$2K
- GSK$2K
- Sanofi-aventis U.S. LLC$2K
- Amgen$2K
- Cumberland Pharmaceuticals, Inc.$2K
- plus $9K from 29 others
What the payments were for
- Food & beverage$26,696100%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 326 | $7,194 |
| AbbVie(2 entities) | 152 | $2,376 |
| GSK | 123 | $2,126 |
| Sanofi-aventis U.S. LLC | 107 | $1,949 |
| Amgen(2 entities) | 87 | $1,937 |
| Cumberland Pharmaceuticals, Inc. | 68 | $1,907 |
| Lilly USA, LLC | 102 | $1,819 |
| Novo Nordisk | 95 | $1,726 |
| Bayer | 46 | $986 |
| Boehringer Ingelheim | 31 | $675 |
| Esperion Therapeutics, Inc. | 28 | $635 |
| Endo Pharmaceuticals Inc. | 22 | $437 |
| Merck | 23 | $424 |
| Xeris Pharmaceuticals, Inc. | 16 | $360 |
| Kowa Pharmaceuticals America, Inc. | 12 | $315 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $255 |
| Johnson & Johnson | 17 | $238 |
| Mylan Specialty L.p. | 9 | $194 |
| Pfizer | 10 | $188 |
| Impel Pharmaceuticals Inc. | 9 | $181 |
| Currax Pharmaceuticals LLC | 12 | $169 |
| Amarin Pharma, Inc. | 8 | $168 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $70 |
| Ironwood Pharmaceuticals, Inc | 3 | $46 |
| Eisai Inc. | 2 | $42 |
| Novartis | 2 | $26 |
| Viatris Specialty LLC | 1 | $26 |
| Exact Sciences | 1 | $20 |
| Genentech USA, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Aytu Biopharma, Inc. | 1 | $16 |
| Cook Medical LLC | 1 | $16 |
| Astellas Pharma US Inc | 1 | $12 |
| Zyla Life Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,724 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Losartan Potassium | 16 | $292 |
| Metformin Hcl | 15 | $201 |
| Amlodipine Besylate | 27 | $193 |
| Metoprolol Succinate | 11 | $184 |
| Levothyroxine Sodium | 16 | $102 |
| Prednisone | 29 | $67 |
| Lisinopril | 16 | $66 |
| Rosuvastatin Calcium | 11 | $55 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Manassas
- Grace StonerockManassas$18K
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
- Catherine VarneyZion Crossroads$47K
- Jordan TranWinchester$42K
- John ClayColonial Heights$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.